(EMAILWIRE.COM, November 29, 2018 ) Browse 170 market data tables and 37 figures spread through 252 pages and in-depth TOC on “Drug Delivery Technology Market”
https://www.marketsandmarkets.com/Market-Reports/drug-delivery-technologies-market-1085.html
Early buyers will receive 10% customization on this report.

Owing to the lack of innovation due to decreased R&D expenditures, the pharmaceutical industry is witnessing a slowdown in branded drug formulations and technologies. This has resulted in an increasing number of generics flooding the market and a loss in the annual sales of branded drugs.

Thus, big pharmaceutical companies are increasingly being pressurized to provide differentiated products from those of their competitors. Also, in recent years, patents for blockbuster drugs of these companies are set to expire in the near future. Reformulation of drugs through drug delivery technologies help in product differentiation strategies and provide a lucrative and less expensive option to extend patent expirations. At the same time, the technologies help to retain market leadership, protect sales revenue, and bring competitive value to the pharmaceutical firms.

Download the PDF Brochure@ http://bit.ly/2KCByBG

Product launches and approvals accounted for the largest share of the total strategic developments in the drug delivery technology market from January 2014 to November 2016. The major players that adopted these strategies include Johnson & Johnson (U.S.), Pfizer, Inc. (U.S.), and Novartis AG (Switzerland).

Johnson & Johnson adopted organic as well as inorganic growth strategies to expand its presence in the drug delivery technology market. For instance, in February 2016, McNeil Consumer Healthcare, a part of Johnson & Johnson, introduced RHINOCORT Allergy Spray, used for treating nasal allergies. In addition, in June 2015, the company introduced Invega Trinza in the U.S.; this antipsychotic drug is used for the treatment of schizophrenia.

Moreover, the company is focused on obtaining approvals for the timely launch its products in the market and thereby strengthening its customer base. For instance, in September 2016, Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, received the FDA approval for its INVOKAMET XR, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR) for the treatment of type 2 diabetes.

Novartis AG (Switzerland) is one of the top players in the drug delivery technology market. Company’s leading position can be attributed to its strong brand recognition and robust product portfolio. In order to maintain its leading position, the company significantly invests in R&D activities. This investment helped the company develop and launch new and advanced products in the drug delivery technology market.

Get the Sample Pages for More Details@ http://bit.ly/2AthME1

For instance, in October 2016, Alcon, a division of Novartis, launched CyPass Micro-Stent at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago, U.S. The company also focuses on inorganic growth strategies to sustain its foothold in the market. For instance, in June 2016, Novartis entered into a licensing and collaboration agreement with Xencor (U.S.) to develop bispecific antibodies to treat cancer.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com